The 505(b)(2) Advantage: “Hybrid” is the Power Move in 2026
February 16, 2026
Successful Phase I Clinical Trials Can Improve Medical Patent Value
February 23, 2026
Medical Patents Broker Inc. By Kenneth Pearce, President
In the medical technology sector, the clock is often as important as the claim. One of the most significant mistakes an inventor or a small firm can make is allowing a patent to expire before exploring its full market potential.
Once a patent expires, the proprietary “moat” disappears, and the technology essentially becomes public property. At that point, the opportunity for a sale or license effectively vanishes.
The “Maintenance” Trap Many patents expire not because the technology failed, but because of missed maintenance fees or a lack of a strategic timeline.
- The Cost of Inaction: Maintenance fees increase over the life of a patent. If an inventor is not seeing immediate market traction, they may view these fees as a burden rather than an investment.
- The Buyer’s Perspective: A corporate buyer or licensee is not just buying an idea; they are buying time. If a patent has only a few years of life remaining, the buyer may not have enough time to clear the FDA and achieve a return on investment.
- The Regulatory Gap: If the FDA pathway takes 5 years and the patent expires in 4, the asset may be functionally worthless to a commercial partner.
Strategic Timing MPB has observed that the “sweet spot” for a transaction is often while the patent still has significant “runway.” Waiting until the final years of a patent’s life to seek a buyer often results in a steep discount in price—or no interest at all.
Innovation requires a bridge to the market, but that bridge must be crossed before the clock runs out. If you have an active patent, the time to evaluate its marketability is while the legal protections are still robust.
